多形核髓系来源抑制细胞是单倍体造血干细胞移植中挽救自然杀伤细胞移植物抗白血病活性的新靶点。 - Suppr | 超能文献

PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.

作者信息

Tumino Nicola, Besi Francesca, Di Pace Anna Laura, Mariotti Francesca Romana, Merli Pietro, Li Pira Giuseppina, Galaverna Federica, Pitisci Angela, Ingegnere Tiziano, Pelosi Andrea, Quatrini Linda, Munari Enrico, Locatelli Franco, Moretta Lorenzo, Vacca Paola

机构信息

Immunology Research Area, IRCCS Bambino Gesù Pediatric Hospital, Rome, Italy.

Department of Pediatric Hematology/Oncology, IRCCS Bambino Gesù Children's Hospital, Rome, Italy.

出版信息

Leukemia. 2020 Mar;34(3):932-937. doi: 10.1038/s41375-019-0585-7. Epub 2019 Oct 4.

DOI:10.1038/s41375-019-0585-7

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7214239/

Abstract

摘要

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

文档翻译

学术文献翻译模型，支持多种主流文档格式。

相似文献

1

PMN-MDSC are a new target to rescue graft-versus-leukemia activity of NK cells in haplo-HSC transplantation.

Leukemia. 2020 Mar;34(3):932-937. doi: 10.1038/s41375-019-0585-7. Epub 2019 Oct 4.

2

NK Cells Mediate a Crucial Graft-versus-Leukemia Effect in Haploidentical-HSCT to Cure High-Risk Acute Leukemia.

Trends Immunol. 2018 Jul;39(7):577-590. doi: 10.1016/j.it.2018.04.009. Epub 2018 May 21.

3

Immunology. A perfect mismatch.

Science. 2002 Mar 15;295(5562):2029-31. doi: 10.1126/science.1070538.

4

Natural killer cell alloreactivity in allogeneic hematopoietic transplantation.

Curr Opin Oncol. 2007 Mar;19(2):142-7. doi: 10.1097/CCO.0b013e3280148a1a.

5

Natural killer cells: From surface receptors to the cure of high-risk leukemia (Ceppellini Lecture).

HLA. 2019 Apr;93(4):185-194. doi: 10.1111/tan.13509.

6

Role of alloreactive KIR2DS1(+) NK cells in haploidentical hematopoietic stem cell transplantation.

J Leukoc Biol. 2011 Oct;90(4):661-7. doi: 10.1189/jlb.0311137. Epub 2011 Jul 26.

7

Expansion of NKG2A-LIR1- natural killer cells in HLA-matched, killer cell immunoglobulin-like receptors/HLA-ligand mismatched patients following hematopoietic cell transplantation.

Biol Blood Marrow Transplant. 2010 Apr;16(4):469-81. doi: 10.1016/j.bbmt.2009.12.008. Epub 2010 Jan 4.

8

Expression of KIR2DS1 does not significantly contribute to NK cell cytotoxicity in HLA-C1/C2 heterozygous haplotype B donors.

Int Immunol. 2017 Nov 1;29(9):423-429. doi: 10.1093/intimm/dxx052.

9

NK cells: a lesson from mismatched hematopoietic transplantation.

Trends Immunol. 2002 Sep;23(9):438-44. doi: 10.1016/s1471-4906(02)02284-6.

10

Anti-leukemia activity of alloreactive NK cells in KIR ligand-mismatched haploidentical HSCT for pediatric patients: evaluation of the functional role of activating KIR and redefinition of inhibitory KIR specificity.

Blood. 2009 Mar 26;113(13):3119-29. doi: 10.1182/blood-2008-06-164103. Epub 2008 Oct 22.

引用本文的文献

1

The AML immune paradox: decoding escape pathways and pioneering checkpoint, vaccine, and combination strategies.

Clin Exp Med. 2025 Jul 9;25(1):240. doi: 10.1007/s10238-025-01795-9.

2

Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens.

Clin Exp Med. 2025 Jun 24;25(1):215. doi: 10.1007/s10238-025-01764-2.

3

Tumor‑associated neutrophils: Critical regulators in cancer progression and therapeutic resistance (Review).

Int J Oncol. 2025 Apr;66(4). doi: 10.3892/ijo.2025.5734. Epub 2025 Feb 28.

4

The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer.

Cancer Rep (Hoboken). 2025 Feb;8(2):e70044. doi: 10.1002/cnr2.70044.

5

Tumor-derived G-CSF induces an immunosuppressive microenvironment in an osteosarcoma model, reducing response to CAR.GD2 T-cells.

J Hematol Oncol. 2024 Dec 18;17(1):127. doi: 10.1186/s13045-024-01641-7.

6

The Interactions of T Cells with Myeloid-Derived Suppressor Cells in Peripheral Blood Stem Cell Grafts.

Cells. 2024 Sep 14;13(18):1545. doi: 10.3390/cells13181545.

7

Immune-dysregulation harnessing in myeloid neoplasms.

Cancer Med. 2024 Sep;13(17):e70152. doi: 10.1002/cam4.70152.

8

Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.

Biomark Res. 2023 Mar 29;11(1):34. doi: 10.1186/s40364-023-00475-8.

9

Different effects of NK cells and NK-derived soluble factors on cell lines derived from primary or metastatic pancreatic cancers.

Cancer Immunol Immunother. 2023 Jun;72(6):1417-1428. doi: 10.1007/s00262-022-03340-z. Epub 2022 Nov 30.

10

Strategies for Potentiating NK-Mediated Neuroblastoma Surveillance in Autologous or HLA-Haploidentical Hematopoietic Stem Cell Transplants.

Cancers (Basel). 2022 Sep 20;14(19):4548. doi: 10.3390/cancers14194548.